|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,951.50 INR | +0.46% |
|
+2.53% | +13.48% |
| 07:04pm | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| 09:53am | Sun Pharma Wins South Africa Approval for Generic Semaglutide | MT |
| Market Cap | 4,682B 48.66B 42.54B 39.25B 36.08B 68.36B 69.53B 469B 184B 2,289B 183B 179B 7,888B | P/E 2027 * |
35.6x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4,409B 45.82B 40.06B 36.96B 33.97B 64.37B 65.47B 441B 173B 2,155B 172B 168B 7,428B | EV / Sales 2027 * |
6.74x | EV / Sales 2028 * | 5.95x |
| Free-Float |
44.39% | Yield 2027 * |
0.81% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.46% | ||
| 1 week | +2.53% | ||
| Current month | +4.78% | ||
| 1 month | +7.95% | ||
| 3 months | +18.12% | ||
| 6 months | +14.75% | ||
| Current year | +13.48% |
| 1 week | 1,888.2 |  | 1,962.7 |
| 1 month | 1,792.6 | | 1,962.7 |
| Current year | 1,583.7 | | 1,962.7 |
| 1 year | 1,548 | | 1,962.7 |
| 3 years | 1,063.85 | | 1,962.7 |
| 5 years | 672.55 | | 1,962.7 |
| 10 years | 312 | | 1,962.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.46% | +2.53% | +15.98% | +81.88% | 48.52B | |
| -0.36% | -4.82% | +65.56% | +115.03% | 35.68B | |
| -0.01% | -0.95% | -3.10% | +39.49% | 12.09B | |
| +2.06% | +0.34% | +19.46% | +94.32% | 11.77B | |
| +1.13% | +0.38% | +32.83% | +126.50% | 9.19B | |
| -1.81% | -2.85% | +45.77% | -5.83% | 7.06B | |
| -0.17% | 0.00% | +18.91% | +37.57% | 7.01B | |
| -0.33% | +1.43% | +3.52% | +227.22% | 6.77B | |
| +6.39% | -0.15% | -14.91% | +20.63% | 5.98B | |
| +1.33% | +4.21% | +30.52% | +139.19% | 4.43B | |
| Average | +0.87% | +0.66% | +21.46% | +87.60% | 14.85B | |
| Weighted average by Cap. | +0.48% | -0.17% | +27.83% | +89.75% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.8B 5.94B 5.48B 5.04B 9.55B 9.71B 65.45B 25.68B 320B 25.53B 24.97B 1,102B | 729B 7.58B 6.63B 6.11B 5.62B 10.65B 10.83B 72.98B 28.64B 356B 28.47B 27.84B 1,229B |
| Net income | 133B 1.38B 1.2B 1.11B 1.02B 1.94B 1.97B 13.27B 5.21B 64.81B 5.17B 5.06B 223B | 157B 1.63B 1.42B 1.31B 1.21B 2.29B 2.32B 15.67B 6.15B 76.53B 6.11B 5.98B 264B |
| Net Debt | -273B -2.84B -2.48B -2.29B -2.11B -3.99B -4.06B -27.34B -10.73B -134B -10.66B -10.43B -460B | -341B -3.55B -3.1B -2.86B -2.63B -4.99B -5.07B -34.17B -13.41B -167B -13.33B -13.04B -575B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/07/26 | ₹1,951.50 | +0.46% | 2,283,494 |
| 14/07/26 | ₹1,942.60 | +1.10% | 2,822,124 |
| 13/07/26 | ₹1,921.40 | -0.73% | 1,573,176 |
| 10/07/26 | ₹1,935.50 | -0.17% | 1,478,172 |
| 09/07/26 | ₹1,938.70 | +2.67% | 4,446,201 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
